HJC0152 suppresses human non–small‐cell lung cancer by inhibiting STAT3 and modulating metabolism
Lu Lu(Shanghai Medical College of Fudan University), Qiang Shen(Peking University), Jun Rao(Jiangxi Provincial Cancer Hospital), Jia Zhou(Io Therapeutics (United States)), Hang Li, Saijun Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin Wu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 27
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
|JNCI Journal of the National Cancer Institute|1999|558
BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells
|Science|1999|494